United States: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
CMS Imposes Prohibition On Federal Medicaid And CHIP Payment For Certain Gender-Affirming Healthcare For Minors: What Providers Need To Know
The Centers for Medicare and Medicaid Services has issued a Final Rule prohibiting federal Medicaid and CHIP reimbursement for certain gender-affirming healthcare treatments for minors, including puberty blockers, cross-sex hormone therapy, and surgical interventions. The purpose-based restriction creates exceptions for the same treatments when used for other medical purposes, while maintaining coverage for mental health counseling and medically verifiable disorders of sexual development.
United States Healthcare
BB
Bass, Berry & Sims
Article
$46 Million Veloxis Settlement Yields Record Sunshine Penalty And Insights Into DOJ’s Cross-Agency Data Use
The U.S. Department of Justice announced a landmark $46 million settlement with Veloxis Pharmaceuticals for allegedly paying healthcare professionals kickbacks through lavish meals, luxury trips, and sham consulting arrangements to induce prescriptions of its kidney transplant drug. The resolution includes criminal penalties, civil settlements, and a record-breaking $1.55 million penalty for Sunshine Act violations, marking the largest such recovery since the law's passage in 2010. This case demonstrates DO
United States Healthcare
GP
Goodwin Procter LLP
Article
CMS’s Final Rule Bans Federal Medicaid Funding For Youth Gender-Affirming Care
The Centers for Medicare and Medicaid Services has issued a final rule prohibiting federal Medicaid and CHIP funding for gender-affirming care for minors, effective October 2026. This comprehensive analysis examines the rule's scope, legal framework, state-by-state implications, and operational impacts on healthcare providers, insurers, and families navigating coverage restrictions.
United States Healthcare
CM
Crowell & Moring LLP
See more

Highlighted Content

Food and Drugs Law

Article
CMS Imposes Prohibition On Federal Medicaid And CHIP Payment For Certain Gender-Affirming Healthcare For Minors: What Providers Need To Know
The Centers for Medicare and Medicaid Services has issued a Final Rule prohibiting federal Medicaid and CHIP reimbursement for certain gender-affirming healthcare treatments for minors, including puberty blockers, cross-sex hormone therapy, and surgical interventions. The purpose-based restriction creates exceptions for the same treatments when used for other medical purposes, while maintaining coverage for mental health counseling and medically verifiable disorders of sexual development.
United States Healthcare
BB
Bass, Berry & Sims
Article
Key Takeaways From The CY 2027 Medicare Physician Fee Schedule Proposed Rule
The Centers for Medicare & Medicaid Services has issued a proposed rule announcing significant policy changes for Medicare payments under the physician fee schedule and other Medicare Part B issues, effective January 1, 2027. The Proposed Rule introduces new restrictions on remote patient monitoring services, restructures practice expense methodology, proposes payment reductions for same-day evaluation...
United States Healthcare
GP
Goodwin Procter LLP
See more

Life Sciences, Biotechnology & Nanotechnology

Article
CMS’s Final Rule Bans Federal Medicaid Funding For Youth Gender-Affirming Care
The Centers for Medicare and Medicaid Services has issued a final rule prohibiting federal Medicaid and CHIP funding for gender-affirming care for minors, effective October 2026. This comprehensive analysis examines the rule's scope, legal framework, state-by-state implications, and operational impacts on healthcare providers, insurers, and families navigating coverage restrictions.
United States Healthcare
CM
Crowell & Moring LLP
Article
Key Trends In Life Sciences Transaction Allocations | Insights From 2021-2025
Ankura's comprehensive insights hub showcases cutting-edge analysis across cybersecurity threats, life sciences transactions, regulatory compliance, and corporate governance. Explore how emerging malware campaigns, building envelope litigation patterns, and evolving valuation landscapes are reshaping risk management and strategic decision-making for enterprises worldwide.
United States Healthcare
AC
Ankura Consulting Group LLC
See more

Healthcare

Article
CMS Imposes Prohibition On Federal Medicaid And CHIP Payment For Certain Gender-Affirming Healthcare For Minors: What Providers Need To Know
The Centers for Medicare and Medicaid Services has issued a Final Rule prohibiting federal Medicaid and CHIP reimbursement for certain gender-affirming healthcare treatments for minors, including puberty blockers, cross-sex hormone therapy, and surgical interventions. The purpose-based restriction creates exceptions for the same treatments when used for other medical purposes, while maintaining coverage for mental health counseling and medically verifiable disorders of sexual development.
United States Healthcare
BB
Bass, Berry & Sims
Article
$46 Million Veloxis Settlement Yields Record Sunshine Penalty And Insights Into DOJ’s Cross-Agency Data Use
The U.S. Department of Justice announced a landmark $46 million settlement with Veloxis Pharmaceuticals for allegedly paying healthcare professionals kickbacks through lavish meals, luxury trips, and sham consulting arrangements to induce prescriptions of its kidney transplant drug. The resolution includes criminal penalties, civil settlements, and a record-breaking $1.55 million penalty for Sunshine Act violations, marking the largest such recovery since the law's passage in 2010. This case demonstrates DO
United States Healthcare
GP
Goodwin Procter LLP
See more

Latest Videos

See more